Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients

Charpentier, G.; Fleury, Fabrice; Kabir, M S; Vaur, L; Halimi, Serge

doi:10.1046/j.1464-5491.2001.00582.x

Cited by 133 publications

(93 citation statements)

References 21 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This coincides with a study conducted by Charpentier et al, Wang et al, and Pareek et al, [13][14][15] who showed a significant reduction in FBS and PPBS (P < 0.001) from baseline than either glimepiride or metformin alone. The results of the present study coincide with these studies where FBS and PPBS decreased significantly (P < 0.01) from baseline to 12 weeks (P < 0.001).…”

Section: Discussionsupporting

confidence: 71%

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Gullapalli¹,

Desai²

2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis, renoretinal microangiopathy, and neuropathy leading to a variety of vascular, neurological, and focal complications. Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients with Type 2 diabetes mellitus. Materials and Methods: This is a longitudinal interventional study. A total of 60 patients were enrolled in the study. Those patients who were already on metformin 500 mg bid with poor glycemic control were included in the study. These 60 patients were divided into two groups each consisting of 30 patients. Group A patients received glimepiride 1 mg bid and metformin 500 mg bid. Group B patients received vildagliptin 50 mg bid and metformin 500 mg bid. The total period of the study was 3 months. Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A 1c (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA 1C in B group. The reduction of HbA 1C was not statistically significant between the two groups. Adverse effects were more with metformin and glimepiride group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups. Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of glimepiride and metformin combination and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain.

show abstract

Section: Discussionsupporting

confidence: 71%

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Gullapalli¹,

Desai²

2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

show abstract

“…[16][17][18][19] A 16weeks of combination therapy of metformin and teneligliptin by Kim MK et al reported similar significant decrease of FPS and HBA1c in their study. 20 So also a 12weeks study by Kadowaki T et al of glimepiride and teneligliptin combination found effective reduction in FPS, PPS and HBA1c and reduction in HBA1c was maintained even at 52weeks.…”

supporting

confidence: 58%

Study of glycemic response of oral anti-diabetic drugs in type 2 diabetic patients

Shashikala

Rao

2018

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Type 2 Diabetes Mellitus (T2DM) is one of the most common non-communicable diseases associated with short term and long term avoidable complications. The treatment of T2DM often is initiated with monotherapy of oral antidiabetic drugs, which often do not decrease the plasma sugar levels effectively and consistently that will reduce the complications associated with T2DM. Hence the current study is aimed to determine the effectiveness of commonly available and affordable oral anti-diabetic drugs (OADs) in type 2 diabetic patients.Methods: This study consisted of 210 T2 Diabetic patients, 120 males and 90 females with a mean age of 50.93yrs were divided equally into six groups with equal number of males and females in each group depending upon the OADs they received in solo or in combination for 24weeks. After the written consent, a detail Clinical history, Clinical examination, Biochemical investigations including, Fasting plasma sugar (FPS), Post prandial sugar (PPS), Glycosylated heamoglobin (HBA1c), serum Creatinine, serum Electrolytes, Chest X-ray PA view and standard ECG were done. Repeat FPS, PPS and HBA1c were done after 4, 12 and 24weeks of study.Results: After 4 weeks, FPS, PPS decreased significantly in combination therapy (p <0.05), while after 12weeks and 24weeks of study, FPS, PPS and HBA1c decreased significantly (p <0.01 to p <0.001 in both monotherapy and in combination therapy. Non-diabetic levels of plasma sugars were obtained in 25-45% with monotherapy and 37-57% in combination therapy. Metformin was an effective monotherapy to initiate treatment of T2DM, but eventually combination therapy was required in most of the patients. The combinations of metformin-teneligliptin and metformin-glimepiride were found to be most effective because of their favourable pharmacokinetic characters and complementary pharmcodynamic effects.Conclusions: OADs are affordable, effective hypoglycemic agents to initiate treatment as monotherapy and for subsequent treatment as combination therapy for T2DM.

show abstract

“…The improvements in glycaemic parameters with glimepiride and metformin were similar, while combination produced a lower degree of reduction with respect to the change in FBG [26,27,28]. The previous studies approved that glimepiride increases insulin sensitivity at peripheral target sites and improve glycemic control in newly diagnosed diabetic subjects, The extrapancreatic effects of glimepiride made its combination with metformin more effective in improving glycemic control by reducing glucose level [29,30].…”

Section: Discussionmentioning

confidence: 99%

Effect of Metformin on Lipid profile of type II Diabetes

Garimella¹,

Seshayamma²,

Rao³

et al. 2016

IJIMS

View full text Add to dashboard Cite

Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients

Abstract: Addition of glimepiride to metformin in Type 2 diabetic patients inadequately controlled by metformin alone resulted in superior glycaemic control compared with glimepiride or metformin monotherapy.

Cited by 133 publications

References 21 publications

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Study of glycemic response of oral anti-diabetic drugs in type 2 diabetic patients

Effect of Metformin on Lipid profile of type II Diabetes

Contact Info

Product

Resources

About